Elenagen, a novel DNA immunotherapy for the deadliest form of ovarian cancer, delays disease progression
BOSTON, February 22, 2024: CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to ...